 Michael Wachs
Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 57 | 2023 | 830 | 3.660 |
Why?
| | Living Donors | 18 | 2023 | 324 | 0.970 |
Why?
| | Liver Neoplasms | 9 | 2023 | 521 | 0.830 |
Why?
| | Donor Selection | 3 | 2021 | 73 | 0.760 |
Why?
| | Tissue Donors | 4 | 2021 | 331 | 0.750 |
Why?
| | Airway Extubation | 2 | 2022 | 45 | 0.710 |
Why?
| | Carcinoma, Hepatocellular | 7 | 2010 | 224 | 0.580 |
Why?
| | Immunosuppressive Agents | 16 | 2013 | 666 | 0.580 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 130 | 0.480 |
Why?
| | Graft Survival | 15 | 2023 | 480 | 0.470 |
Why?
| | Hepatoblastoma | 2 | 2023 | 25 | 0.450 |
Why?
| | Cholestasis | 1 | 2016 | 225 | 0.430 |
Why?
| | Sirolimus | 8 | 2013 | 192 | 0.410 |
Why?
| | Hypoxia | 1 | 2016 | 937 | 0.350 |
Why?
| | Biliary Atresia | 2 | 2022 | 185 | 0.320 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2006 | 39 | 0.310 |
Why?
| | Liver Failure | 5 | 2008 | 84 | 0.280 |
Why?
| | Retrospective Studies | 23 | 2023 | 12608 | 0.270 |
Why?
| | Graft Rejection | 10 | 2008 | 533 | 0.270 |
Why?
| | Tissue and Organ Procurement | 6 | 2022 | 243 | 0.270 |
Why?
| | Treatment Outcome | 20 | 2023 | 9159 | 0.270 |
Why?
| | Portal Vein | 1 | 2006 | 81 | 0.260 |
Why?
| | Venous Thrombosis | 1 | 2006 | 145 | 0.240 |
Why?
| | Vena Cava, Inferior | 1 | 2004 | 55 | 0.220 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 74 | 0.200 |
Why?
| | Sarcoma | 1 | 2023 | 137 | 0.200 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2021 | 25 | 0.190 |
Why?
| | Middle Aged | 34 | 2021 | 26999 | 0.190 |
Why?
| | Vascular Surgical Procedures | 1 | 2004 | 262 | 0.190 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 228 | 0.190 |
Why?
| | Humans | 64 | 2023 | 115587 | 0.180 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 74 | 0.180 |
Why?
| | Cause of Death | 3 | 2021 | 368 | 0.170 |
Why?
| | Child | 12 | 2023 | 18488 | 0.170 |
Why?
| | Kidney Transplantation | 4 | 2003 | 558 | 0.160 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 243 | 0.160 |
Why?
| | Cyclosporine | 8 | 2008 | 169 | 0.160 |
Why?
| | Liver | 7 | 2022 | 1690 | 0.160 |
Why?
| | Tacrolimus | 8 | 2008 | 143 | 0.150 |
Why?
| | Hepatitis B | 2 | 1996 | 53 | 0.150 |
Why?
| | Reoperation | 4 | 2016 | 525 | 0.150 |
Why?
| | Waiting Lists | 3 | 2022 | 223 | 0.150 |
Why?
| | Drug Overdose | 1 | 2021 | 296 | 0.140 |
Why?
| | Male | 38 | 2021 | 55949 | 0.140 |
Why?
| | Time Factors | 10 | 2021 | 6165 | 0.140 |
Why?
| | Liver Cirrhosis | 3 | 2013 | 238 | 0.140 |
Why?
| | Hepatitis C | 2 | 2013 | 229 | 0.140 |
Why?
| | Pancreas Transplantation | 3 | 2003 | 64 | 0.140 |
Why?
| | Adult | 26 | 2021 | 30718 | 0.130 |
Why?
| | Hepatic Artery | 3 | 2004 | 52 | 0.130 |
Why?
| | Female | 37 | 2021 | 59913 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 646 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2010 | 863 | 0.130 |
Why?
| | Hepatitis B Core Antigens | 1 | 1995 | 5 | 0.130 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 19 | 0.120 |
Why?
| | Shock | 1 | 2016 | 76 | 0.120 |
Why?
| | Hepatitis, Autoimmune | 2 | 2008 | 32 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 422 | 0.120 |
Why?
| | Postoperative Complications | 5 | 2021 | 2161 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2016 | 187 | 0.120 |
Why?
| | Muromonab-CD3 | 3 | 2010 | 23 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 312 | 0.110 |
Why?
| | Cadaver | 3 | 2004 | 316 | 0.110 |
Why?
| | Immunoglobulin M | 1 | 1995 | 254 | 0.110 |
Why?
| | Glucocorticoids | 4 | 2003 | 552 | 0.110 |
Why?
| | Risk Factors | 7 | 2021 | 8697 | 0.110 |
Why?
| | Methylene Blue | 1 | 2012 | 23 | 0.100 |
Why?
| | Hepatectomy | 2 | 2008 | 137 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 113 | 0.100 |
Why?
| | Adolescent | 8 | 2022 | 17889 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2013 | 207 | 0.100 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 16 | 0.100 |
Why?
| | Triiodothyronine | 1 | 2011 | 43 | 0.090 |
Why?
| | Thyroxine | 1 | 2011 | 59 | 0.090 |
Why?
| | Hypotension | 1 | 2012 | 115 | 0.090 |
Why?
| | Hypothyroidism | 1 | 2011 | 65 | 0.090 |
Why?
| | Mycophenolic Acid | 3 | 2008 | 81 | 0.090 |
Why?
| | Portography | 2 | 2006 | 13 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 757 | 0.080 |
Why?
| | Budd-Chiari Syndrome | 2 | 1999 | 8 | 0.080 |
Why?
| | Heart Transplantation | 1 | 1995 | 671 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 337 | 0.080 |
Why?
| | Infant | 4 | 2022 | 7979 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2008 | 509 | 0.080 |
Why?
| | Hepatic Veins | 1 | 2008 | 31 | 0.080 |
Why?
| | Chemoembolization, Therapeutic | 2 | 2007 | 49 | 0.080 |
Why?
| | Liver Diseases | 4 | 2002 | 263 | 0.080 |
Why?
| | Biomarkers | 2 | 2016 | 3466 | 0.070 |
Why?
| | Risk Assessment | 4 | 2022 | 2987 | 0.070 |
Why?
| | Calcineurin Inhibitors | 2 | 2008 | 59 | 0.070 |
Why?
| | Recurrence | 5 | 2013 | 952 | 0.070 |
Why?
| | Follow-Up Studies | 6 | 2008 | 4440 | 0.070 |
Why?
| | Ultrasonics | 1 | 2006 | 48 | 0.070 |
Why?
| | Prednisone | 2 | 1997 | 232 | 0.070 |
Why?
| | Patient Selection | 4 | 2004 | 654 | 0.070 |
Why?
| | Disease Transmission, Infectious | 1 | 2006 | 57 | 0.070 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 30 | 0.060 |
Why?
| | Bile Ducts | 2 | 2022 | 73 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2006 | 88 | 0.060 |
Why?
| | Treatment Failure | 1 | 2006 | 332 | 0.060 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 154 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 10470 | 0.060 |
Why?
| | Intestinal Fistula | 1 | 2004 | 12 | 0.060 |
Why?
| | Vascular Fistula | 1 | 2004 | 15 | 0.060 |
Why?
| | Duodenal Diseases | 1 | 2004 | 10 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2004 | 46 | 0.060 |
Why?
| | Transplants | 1 | 2004 | 37 | 0.060 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 25 | 0.060 |
Why?
| | Outpatients | 1 | 2006 | 330 | 0.060 |
Why?
| | Ultrasonography | 1 | 2006 | 641 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 14 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 197 | 0.050 |
Why?
| | Hospital Costs | 1 | 2003 | 105 | 0.050 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 68 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2022 | 53 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2006 | 2392 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 430 | 0.050 |
Why?
| | Hepatic Encephalopathy | 2 | 1999 | 21 | 0.050 |
Why?
| | Fibrinolysis | 1 | 2023 | 160 | 0.050 |
Why?
| | Survival Analysis | 4 | 2008 | 1219 | 0.050 |
Why?
| | Liver Failure, Acute | 2 | 1998 | 60 | 0.050 |
Why?
| | Aged | 10 | 2021 | 19251 | 0.050 |
Why?
| | Drug Therapy, Combination | 4 | 2008 | 962 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2001 | 124 | 0.040 |
Why?
| | Child, Preschool | 3 | 2022 | 9133 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 240 | 0.040 |
Why?
| | Prednisolone | 1 | 1999 | 77 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 477 | 0.040 |
Why?
| | Biopsy | 4 | 2006 | 1056 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2022 | 526 | 0.040 |
Why?
| | Mesenteric Veins | 1 | 1998 | 10 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 140 | 0.040 |
Why?
| | United States | 3 | 2023 | 12295 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 2907 | 0.040 |
Why?
| | Ascites | 2 | 2013 | 35 | 0.040 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 1997 | 7 | 0.040 |
Why?
| | Thrombectomy | 1 | 1998 | 53 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 958 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 1998 | 118 | 0.040 |
Why?
| | Critical Illness | 1 | 2022 | 645 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 1138 | 0.030 |
Why?
| | Kidney | 1 | 2003 | 1207 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2008 | 621 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1997 | 198 | 0.030 |
Why?
| | Liver Diseases, Alcoholic | 1 | 1997 | 85 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1997 | 92 | 0.030 |
Why?
| | Cryopreservation | 1 | 1997 | 93 | 0.030 |
Why?
| | Diabetes Mellitus | 3 | 2003 | 906 | 0.030 |
Why?
| | Biliary Tract Diseases | 1 | 1996 | 34 | 0.030 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 1996 | 25 | 0.030 |
Why?
| | Cholestasis, Intrahepatic | 1 | 1996 | 40 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 2 | 2008 | 815 | 0.030 |
Why?
| | Hemostasis, Surgical | 1 | 1995 | 21 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3069 | 0.030 |
Why?
| | Survival Rate | 3 | 2010 | 1650 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2008 | 1087 | 0.030 |
Why?
| | Thrombosis | 1 | 1998 | 302 | 0.030 |
Why?
| | Colorado | 4 | 2008 | 4113 | 0.030 |
Why?
| | Health Care Rationing | 2 | 2004 | 47 | 0.030 |
Why?
| | Melanoma | 1 | 2000 | 651 | 0.030 |
Why?
| | Pleural Effusion | 1 | 2013 | 46 | 0.030 |
Why?
| | Hemodynamics | 1 | 1997 | 968 | 0.030 |
Why?
| | Hospitals, University | 2 | 2003 | 172 | 0.030 |
Why?
| | Shock, Surgical | 1 | 2012 | 3 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2012 | 36 | 0.030 |
Why?
| | Hypertension | 2 | 1997 | 1064 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1178 | 0.030 |
Why?
| | Catecholamines | 1 | 2012 | 97 | 0.030 |
Why?
| | Acute Disease | 3 | 1999 | 914 | 0.020 |
Why?
| | Drug Resistance | 1 | 2012 | 162 | 0.020 |
Why?
| | Cyclosporins | 1 | 1990 | 59 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 5077 | 0.020 |
Why?
| | Cohort Studies | 3 | 2008 | 4944 | 0.020 |
Why?
| | Transplantation, Homologous | 3 | 2000 | 397 | 0.020 |
Why?
| | Intestine, Small | 1 | 1990 | 125 | 0.020 |
Why?
| | Phlebography | 2 | 1999 | 40 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2003 | 1870 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 69 | 0.020 |
Why?
| | Incidence | 2 | 2007 | 2335 | 0.020 |
Why?
| | Functional Laterality | 1 | 2008 | 201 | 0.020 |
Why?
| | Prospective Studies | 4 | 1999 | 6264 | 0.020 |
Why?
| | Simplexvirus | 1 | 2006 | 82 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 445 | 0.020 |
Why?
| | Blood Vessels | 1 | 2007 | 181 | 0.020 |
Why?
| | Preoperative Care | 1 | 2007 | 318 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3254 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2008 | 354 | 0.010 |
Why?
| | Survival | 1 | 2004 | 37 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1484 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 32 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 2003 | 57 | 0.010 |
Why?
| | Proteinuria | 1 | 2003 | 78 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 105 | 0.010 |
Why?
| | Cost Control | 1 | 2003 | 40 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 102 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 144 | 0.010 |
Why?
| | Cost Savings | 1 | 2003 | 75 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2002 | 87 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2002 | 141 | 0.010 |
Why?
| | History, 20th Century | 1 | 2002 | 273 | 0.010 |
Why?
| | Methylprednisolone | 1 | 2001 | 83 | 0.010 |
Why?
| | Psychology | 1 | 2001 | 83 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2001 | 185 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2000 | 286 | 0.010 |
Why?
| | Pain, Postoperative | 1 | 2001 | 195 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2001 | 309 | 0.010 |
Why?
| | Cholesterol | 1 | 2001 | 369 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1440 | 0.010 |
Why?
| | Risk | 1 | 2002 | 819 | 0.010 |
Why?
| | Bilirubin | 1 | 1999 | 91 | 0.010 |
Why?
| | Triglycerides | 1 | 2001 | 473 | 0.010 |
Why?
| | Postoperative Hemorrhage | 1 | 1999 | 78 | 0.010 |
Why?
| | Streptokinase | 1 | 1998 | 11 | 0.010 |
Why?
| | Serum Albumin | 1 | 1999 | 135 | 0.010 |
Why?
| | HLA-DR Antigens | 1 | 1999 | 221 | 0.010 |
Why?
| | Multiple Organ Failure | 1 | 1999 | 144 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1805 | 0.010 |
Why?
| | Polycythemia Vera | 1 | 1997 | 13 | 0.010 |
Why?
| | Creatine | 1 | 1997 | 51 | 0.010 |
Why?
| | Constriction | 1 | 1997 | 45 | 0.010 |
Why?
| | Liver Circulation | 1 | 1997 | 21 | 0.010 |
Why?
| | Brain Edema | 1 | 1997 | 59 | 0.010 |
Why?
| | Temperance | 1 | 1997 | 14 | 0.010 |
Why?
| | Reperfusion | 1 | 1997 | 38 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 43 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 1997 | 56 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 200 | 0.010 |
Why?
| | Prevalence | 1 | 2003 | 2264 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1999 | 741 | 0.010 |
Why?
| | Coculture Techniques | 1 | 1997 | 202 | 0.010 |
Why?
| | Health Status | 1 | 2001 | 728 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1646 | 0.010 |
Why?
| | Safety | 1 | 1997 | 298 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1997 | 724 | 0.010 |
Why?
| | Fibrinolytic Agents | 1 | 1998 | 233 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2578 | 0.010 |
Why?
| | Carrier State | 1 | 1996 | 55 | 0.010 |
Why?
| | Comorbidity | 1 | 2000 | 1473 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1998 | 1127 | 0.010 |
Why?
| | Lymphocytes | 1 | 1997 | 344 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1168 | 0.010 |
Why?
| | Fibrosis | 1 | 1996 | 457 | 0.010 |
Why?
| | DNA | 1 | 2000 | 1356 | 0.010 |
Why?
| | Chronic Disease | 1 | 1999 | 1598 | 0.010 |
Why?
| | Blood Pressure | 1 | 1999 | 1537 | 0.010 |
Why?
| | Rats, Inbred ACI | 1 | 1990 | 1 | 0.010 |
Why?
| | Rats, Inbred BN | 1 | 1990 | 53 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 1990 | 93 | 0.010 |
Why?
| | Obesity | 1 | 2003 | 2517 | 0.010 |
Why?
| | Disease Progression | 1 | 1997 | 2418 | 0.010 |
Why?
| | Alcoholism | 1 | 1997 | 713 | 0.010 |
Why?
| | Blood Glucose | 1 | 1999 | 1824 | 0.010 |
Why?
| | Quality of Life | 1 | 2001 | 2385 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3022 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2001 | 4665 | 0.010 |
Why?
| | Species Specificity | 1 | 1990 | 552 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 3914 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 1990 | 212 | 0.000 |
Why?
| | Animals | 2 | 1997 | 32102 | 0.000 |
Why?
| | Rats | 1 | 1990 | 5034 | 0.000 |
Why?
| | Mice | 1 | 1997 | 15052 | 0.000 |
Why?
|
|
Wachs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|